|
201 |
Feasibility of a complex psychosocial intervention for families with parental cancer: acceptability, suitability, implementability, and perceived support
Enthalten in Journal of cancer research and clinical oncology Bd. 150, 17.10.2024, Nr. 10, date:10.2024: 1-12
|
|
|
|
202 |
Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study
Enthalten in Leukemia Bd. 38, 25.11.2023, Nr. 1, date:1.2024: 126-135
|
|
|
|
203 |
Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
Enthalten in Journal of hematology & oncology Bd. 15, 5.9.2022, Nr. 1, date:12.2022: 1-15
|
|
|
|
204 |
Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia
Enthalten in BMC cancer Bd. 19, 4.7.2019, Nr. 1, date:12.2019: 1-14
|
|
|
|
205 |
Kapazität der onkologischen Versorgung in deutschen onkologischen Spitzenzentren während der ersten 2 Jahre der COVID-19-Pandemie
Enthalten in Forum Bd. 37, 7.9.2022, Nr. 5, date:10.2022: 372-376
|
|
|
|
206 |
Longitudinal changes in telomere length in PCB-exposed individuals: interaction with CMV infection
Enthalten in Archives of toxicology Bd. 95, 19.3.2021, Nr. 4, date:4.2021: 1517-1520
|
|
|
|
207 |
Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations
Enthalten in Journal of hematology & oncology Bd. 15, 13.5.2022, Nr. 1, date:12.2022: 1-13
|
|
|
|
208 |
Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
Enthalten in BMC pulmonary medicine Bd. 11, 23.5.2011, Nr. 1, date:12.2011: 1-4
|
|
|
|
209 |
Mutant NRAS Q61K is responsible for MAPK pathway activation in the MARIMO cell line and renders these cells independent of the CALR–MPL–JAK2–STAT5 pathway
Enthalten in Leukemia Bd. 32, 8.8.2018, Nr. 9, date:9.2018: 2087-2090
|
|
|
|
210 |
Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia
Enthalten in Leukemia Bd. 37, 13.10.2023, Nr. 12, date:12.2023: 2395-2403
|
|
Administration
